A Less Expensive Post-Op Pain Option Just Hit the Market for Dogs and Cats

PHARMA & PRODUCT NEWS

Cronus Pharma launches the first FDA-approved bioequivalent to Onsior, giving vets a lower-cost NSAID for surgical recovery.

Cronus Pharma, a veterinary pharmaceutical company built around making animal health products more affordable, announced the U.S. launch of Robenacoxib Injection on Aug. 26. The product is the only FDA-approved bioequivalent to Onsior (robenacoxib) Injection, which means practices now have a lower-cost option for a drug many of them already reach for after surgery.

What It's Approved For

Robenacoxib Injection is indicated for controlling postoperative pain and inflammation tied to soft tissue surgery in dogs older than four months, and to orthopedic surgery, ovariohysterectomy, and castration in cats older than four months. In both species, use is limited to a maximum of three days. The injection is now available through national and regional veterinary distributors across the country.

Why a Bioequivalent Matters

For a lot of general practices, especially high-volume spay-neuter clinics and shelters, the cost of a name-brand NSAID adds up fast across a busy surgical schedule. A bioequivalent option gives practices a way to keep offering the same standard of postoperative pain control without the same price tag, which is the whole premise behind Cronus Pharma's approach to the animal health market.

Addressing post-operative pain is imperative in both dogs and cats, said Scott A. Krick, DVM, consulting technical services veterinarian at Cronus Pharma. The launch reflects our commitment to expanding access to FDA-approved bioequivalent medications that support veterinarians, their patients, and pet owners.

The Fine Print Vets Should Know

As with any prescription NSAID, this one comes with real limits. Federal law restricts Robenacoxib Injection to use by or on the order of a licensed veterinarian, and Cronus Pharma is explicit that the drug should not be used for more than three days or in animals younger than four months. The company also notes that serious adverse events, including hepatopathy, have been reported with long-term use of robenacoxib tablets in dogs during a 28-day study, a reminder that the short duration limit on this product is not just a formality.

The Bottom Line

For practices weighing their postoperative pain protocols, this launch adds a genuinely new option to the conversation rather than just another me-too product. A bioequivalent NSAID with the same FDA-approved indications as an established name brand, at a lower cost, is the kind of practical development that quietly changes day-to-day medicine more than the flashier headlines do.

Source: Cronus Pharma LLC product announcement, Aug. 26, 2026.